What do you think?
Valuation in Life Sciences: A Practical Guide
Ratings & Reviews
Friends & Following
Create a free account to discover what your friends think of this book!
Community Reviews
Displaying 1 - 2 of 2 reviews
March 24, 2024
The book is OK, but its authors could've done better. They could have presented the life sciences valuation methods in more understandable language.
If cash flow discounting is a new concept to you, consider postponing this read for a later time. Instead, delve into "Expectations Investing" by Mauboussin as a starting point.
This book may help create a biotech company valuation model to present to others. Its real options example is solid. It can serve as a good template.
Yet, when you wager your nest egg, you need a more robust approach. Relying solely on the methodologies outlined here for investment decisions is not a good idea. Predicting which drug candidates regulators will approve demands extensive expertise. You can't gain that expertise by reading just one small book.
If cash flow discounting is a new concept to you, consider postponing this read for a later time. Instead, delve into "Expectations Investing" by Mauboussin as a starting point.
This book may help create a biotech company valuation model to present to others. Its real options example is solid. It can serve as a good template.
Yet, when you wager your nest egg, you need a more robust approach. Relying solely on the methodologies outlined here for investment decisions is not a good idea. Predicting which drug candidates regulators will approve demands extensive expertise. You can't gain that expertise by reading just one small book.
January 9, 2016
Worth Reading as an introduction book, especially the DCF part. But not very interested in the option evaluation. Moreover, contents are very basic.
Displaying 1 - 2 of 2 reviews